PEGylated Drugs Market dynamics
The main driving force behind the growth of the PEGylated Drugs Market are, the rising of prevalence diseases such as cancer, advancement of biologics sectors, and increasing pharmaceutical industries all across the globe. Additionally, the increasing number of chronic ailments and death rates because of cancer in Canada will provide a boost to the growth of the pegylated drugs on market.
Although the benefits of pegylated drugs are many, but there are some backdrops available as well with it. The side effects happening because of the drugs and the drug failure will make a restraining effect against the growth of the PEGylated Proteins Market during the forecast period.
PEGylated Drugs mainly have three benefits on the body.
According to studies, the pharmacokinetic properties drastically changes in the body along with prolonging the plasma half-life; it also increases the release of drugs in the body and reduces the renal clearance rate.
A thicker hydration film forms on the surface preventing the precipitation and aggregation. The liposome stability is also increased by the modified linkage between lipid derivatives and PEG. Additionally, the flexible chain of PEG produces a hindrance effect which is steric protecting the modification from protease attack increasing the stability of the modification.
The molecular weight of the drugs increases in the body after being modified by PEG that help reducing the glomerular filtration effects during systemic administration. Therefore, it increases the excretion in the urination. Moreover, PEGylated drugs are also responsible for improving the stability in the systemic circulation and prolongs retention time which is highly beneficial in the distribution of the drugs in one's body. Particularly it helps in accumulating macromolecular drugs in inflammatory sites and tumours. Therefore, it increases the span of treatment of the drugs in vivo.
PEGylated Drugs Market Revenue, by Molecule, 2018 (% share)
Sources: MRFR Analysis
PEGylated Drugs Market Segmentation overview
Based on the PEGylated Drugs Market, it is segmented into-
PEGylated Drugs Market, By Molecule
Based on molecule, the PEGylated Proteins Market is further segmented into-
PEGylated Drugs Market, By Indication
Based on indication, the PEGylated Proteins Market is further segmented into
Cancer segment had 60% of the PEGylated Drugs Market share in 2017 owing to the increasing prevalence of diseases that demanded for a development in making effective drugs. The hepatitis segment is expected to grow at a CAGR of 12% over the forecast period. Moreover, the major key players focusing and developing the pegylated drugs using in chronic disease treatments will propel the growth of the market. For example, the market will be highly benefited with the launch of Pegasys drugs used for the treatment of Hepatitis C in adult patients.
PEGylated Drugs Market Share, by Region, 2018 (%)
Sources: MRFR Analysis
PEGylated Drugs Market, by Region
Based on region, the PEGylated Drugs Market is further segmented into-
PEGylated Drugs Market Regional analysis
Globally, the regional PEGylated Drugs Market is divided into Americas, Europe, Asia-Pacific and Middle East and Africa.
The American market is divided into North America and South America. The American market had a market share of 65.73% in 2018. U.S and Canada are the dominating region of the North American market. Canadian PEGylated Drugs Market is expected to witness a market growth of over 5.5% CAGR during the forecast period. The rising in the prevalence of chronic diseases such as cancer is driving the growth of the market. In 2017, more than 2lac people were diagnosed with cancer (as per the report of Canadian Cancer Society) which had emerged the demand of the pegylated drugs in the market.
Europe was the second-largest market in 2018. The European government supporting and investing in reducing chronic diseases is the driving force behind the growth the regional market. The European region is further classified into Western Europe and Eastern Europe. Western Europe is also classified into the UK, Italy, France, Spain and the rest of the Western Europe. Italian PEGylated Drugs Market had a revenue of USD 218 million in 2017 and expected to witness a growth at a CAGR of 9% during the forecast period.
The Asia-Pacific region is further clssified into India, China, Japan, Australia, South Korea and the rest of Asia-Pacific. APAC holds the third-largest position in the regional PEGylated Drugs Market.
The Middle East and Africa is anticipated to witness a significant growth due to the rising application of pegylated drugs for treating the chronic diseases.
Few industry key players operating the market growth are investing in R&D in PEGylated technology is providing a huge boost in the growth of the PEGylated Drugs Market.
In recent times, new PEGylated drugs such as modified drugs using heterobifunctional PEG (X-PEG-Y) as a linker have been launched with the continuous deep research and developments. It is also believed that in future, the continuous modification in the technology will produce more and more effective and better drugs.
Major key players
There are several major key players in the market. The players operating in the PEGylated Drugs Market are focusing on developing and launching new products and expanding their footprints in the global and larger markets.
The report comprises of
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Molecule, Indication|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Bayer AG.|
|Key Market Opportunities||The major companies are rigorously investing in R&D|
|Key Market Drivers||
The valuation of the global PEGylated drugs market is estimated to reach USD 13,503.67 MN. by 2025.
The global PEGylated drugs market is projected to grow at approximately 5.53% CAGR during the forecast period (2019-2025).
High prevalence of chronic diseases such as cancer.
North America holds the largest share in the global PEGylated drugs market, followed by Europe and the Asia Pacific, respectively.
F. Hoffmann-La Roche Ltd., Horizon Therapeutics Plc, Pfizer Inc., UCB S.A., Novo Nordisk A/S, Amgen, Inc., Merck & Co., Inc., AstraZeneca, Bayer AG, and Takeda Pharmaceutical Company Limited, are some of the major players operating in the PEGylated drugs market.